Dis-Chem’s ongoing leadership transition is seen as a pivotal moment for the retailer, potentially restoring investor confidence if the company enhances its execution capabilities. Aheesh Singh, Chief Investment Officer at MP9 Asset Management, noted that the gradual handover of control from the founders, including the resignation of Saul Saltzman as executive director, represents a natural evolution for the business.
Singh remarked, “The founders built Dis-Chem, but new leadership brings structure. If they keep the culture intact while improving execution, investor confidence will increase.”
On Tuesday, Dis-Chem announced that Saltzman, the son of founders Ivan and Lynette Saltzman, will resign as executive director after 19 years, effective February next year. Following his resignation, he will continue to serve on the board as a non-independent, non-executive director, contributing to the group’s strategic direction and governance.
The board expressed appreciation for Saltzman’s dedication and leadership, emphasizing the value of his continued involvement in a new capacity. Singh pointed out that Dis-Chem’s growth now hinges on enhancing supply chain efficiency, improving margins, and transforming its expanding health ecosystem into a significant profit driver. “Growth now depends on execution,” he stated.
Dis-Chem is transitioning from a founder-led retailer to a professionally managed healthcare group. While the Saltzman family remains a major shareholder, day-to-day leadership has shifted to CEO Rui Morais and his team. Singh believes this transition can unlock value if managed effectively.
Saltzman’s departure is part of the gradual loosening of the family’s operational control over the R28 billion retailer. His father, Ivan Saltzman, stepped down as CEO in June 2023, handing leadership to Morais, while remaining on the board. Lynette Saltzman also reduced her involvement in the board in 2022 to focus on the beauty division.
This leadership shift follows a significant share redistribution within the family earlier this year, where brothers Dan and Mark Saltzman inherited R6.8 billion worth of shares, reducing the family holding company’s stake from 29.31% to 4.06%. Each brother now owns 12.62% of Dis-Chem, ensuring overall family control while indicating a generational transition.
Currently, Dis-Chem’s market capitalization stands at R28 billion, lagging behind its main competitor Clicks, which is valued at R81.7 billion.